healthcare

Additional layers of complexity and uncertainty continue to be added to how life sciences companies bring their products to market as more stakeholders become involved in the commercialization process. While much emphasis is placed on company compliance with regulatory requirements – less emphasis has been placed on vendors or global commercial partners. By not having an established auditing, monitoring and surveillance program of third parties, an undue amount of risk and uncertainty can be imposed on drug manufacturers and their products.

Listen to our educational, on-demand presentation about drug safety governance when working with third parties. Our colleagues discuss:

  • The components of an effective governance policy
  • The importance of having established communication channels between companies and third parties, even when stakeholder software and systems are not fully integrated
  • How to protect the value of your drug or product by managing your company’s global responsibly through vendor relationships

For more information on this topic, or to learn how Baker Tilly’s Value Architects™ can help, contact our team.

Darren R. Jones
Principal, CIA
Woman documenting accounting standard changes
Next up

Utility University: accounting updates – new standards